-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
-
Summary
-
Inhibikase Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2020 to 2024.
- Inhibikase Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $367 K, a 95.7% decline year-over-year.
- Inhibikase Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $8.41 M.
- Inhibikase Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$205 K, a 100% decline from 2021.
- Inhibikase Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $41.1 M, a 173% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)